It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
CDSCO to fast-track trials and approval for COVID19 vaccine
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
It is designed to tackle mental health issues
This deal makes Meddo, one of the largest health-tech players in India
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
